Patent intelligence · US
US 9061016
Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
Patent details — US 9061016
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 23, 2015
- Expiration
- Jun 18, 2035
- Applicant
- APREA AB
- Claims
- 19
- CPC classes
- A61K, A61K31/439, A61K31/444, A61K31/496
Quick answer
US 9061016 (Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease) is held by APREA AB. Status: granted. Granted Jun 23, 2015. Expires Jun 18, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- APREA AB
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/439, A61K31/444, A61K31/496, A61K31/519, A61K31/52
More from APREA AB
Related pharmaceutical patents in our USPTO index.
-
US 7902167
Compounds and methods for down-regulating Wrap53 protein by RNA interference
granted -
US 7759361
Azabicyclooctan-3-one derivatives and use thereof
granted -
US 7659278
Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
granted -
US 7348330
1-azabicyclo [2,2,2] octan-3-one derivatives
granted -
US 6921765
1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
expired
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 9061016?
US 9061016 (Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease) is held by APREA AB. Status: granted. Granted Jun 23, 2015. Expires Jun 18, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9061016?
APREA AB is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 9061016 expire?
Our index shows an expiration date of Jun 18, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.